Hi fellow EM folks.
I have just signed up for a new study being done by Xenon Pharmaceuticals in Canada. Xenon is in the process of developing a new drug specifically targeting sodium channels involved in primary EM. The results of the first phase were very promising, so they are now in secondary human trials looking at dosing and other factors (I'm keeping fingers crossed!)
The new study is non-invasive--they just need a saliva sample to look at DNA which participants mail to them. This is a chance to find out if you have primary or secondary EM (results sent to your doctor). To find out more, see the info below and link to sign up.
Cheers,
Dragica
-----------------
The purpose of this genetic research study is not to pre-screen individuals for a clinical trial; it is to identify and/or find genetic factors that may be related to Primary Erythromelalgia and/or other pain conditions, and to provide eligible participants with genetic results should they wish to receive them.
Please feel free to let others in the erythromelalgia community know about our study and share our link http://www.xenon-pharma.com/em-study/.
Xenon Pharmaceuticals Inc.
■■■■■■■■ Gilmore Way
Burnaby, British Columbia
Canada V5G 4W8
Telephone: 1-604-■■■■■■■■
Fax: 1-604-■■■■■■■■
Email: ■■■■■■■■■■■■■■■■■■■■■■■■■ (mailto:research@xenon-pharma.com)